Proda Biotech, Llc
Clinical trials sponsored by Proda Biotech, Llc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cocktail takes on tough pancreatic cancer Results expected Jun 2027 (estimated)
- Can a Tumor-Blood-Vessel drug boost chemotherapy for Triple-Negative breast cancer? Results expected Jul 2027 (estimated)
-
Can a Tumor-Blood-Vessel drug boost chemotherapy for Triple-Negative breast cancer?
Disease control Recruiting nowThis trial tests whether an experimental drug called ProAgio, which targets blood vessels that feed tumors, can safely and effectively combine with the chemotherapy gemcitabine for people with metastatic triple-negative breast cancer. The study includes adults who have already tr…
Phase 1/2 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail takes on tough pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called ProAgio combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer that has spread. Some participants also get an immunotherapy drug (atezolizumab). The main goals are to find a saf…
Phase 1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC